Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARWR NYSEARCA:LABD NYSEARCA:LABU NASDAQ:MDGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$29.72$19.99$9.57▼$31.13$4.11B12.85 million shs3.04 million shsLABDDirexion Daily S&P Biotech Bear 3x Shares$4.95+4.9%$6.01$4.71▼$16.05$79.30M-2.414.94 million shs15.60 million shsLABUDirexion Daily S&P Biotech Bull 3x Shares$78.72-4.9%$67.99$32.55▼$152.58$816.33M31.68 million shs822,161 shsMDGLMadrigal Pharmaceuticals$432.22-1.6%$364.11$200.63▼$457.16$9.76B-1.02374,030 shs190,643 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals0.00%+2.20%+48.67%+88.82%+41.93%LABDDirexion Daily S&P Biotech Bear 3x Shares+4.87%+3.77%-15.09%-32.47%-15.82%LABUDirexion Daily S&P Biotech Bull 3x Shares-4.86%-4.63%+13.89%+33.97%-39.59%MDGLMadrigal Pharmaceuticals-1.65%-0.15%+15.73%+46.23%+85.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$29.72$19.99$9.57▼$31.13$4.11B12.85 million shs3.04 million shsLABDDirexion Daily S&P Biotech Bear 3x Shares$4.95+4.9%$6.01$4.71▼$16.05$79.30M-2.414.94 million shs15.60 million shsLABUDirexion Daily S&P Biotech Bull 3x Shares$78.72-4.9%$67.99$32.55▼$152.58$816.33M31.68 million shs822,161 shsMDGLMadrigal Pharmaceuticals$432.22-1.6%$364.11$200.63▼$457.16$9.76B-1.02374,030 shs190,643 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals0.00%+2.20%+48.67%+88.82%+41.93%LABDDirexion Daily S&P Biotech Bear 3x Shares+4.87%+3.77%-15.09%-32.47%-15.82%LABUDirexion Daily S&P Biotech Bull 3x Shares-4.86%-4.63%+13.89%+33.97%-39.59%MDGLMadrigal Pharmaceuticals-1.65%-0.15%+15.73%+46.23%+85.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARWRArrowhead Pharmaceuticals 3.00Buy$43.1445.16% UpsideLABDDirexion Daily S&P Biotech Bear 3x Shares 0.00N/AN/AN/ALABUDirexion Daily S&P Biotech Bull 3x Shares 2.71Moderate Buy$78.72N/AMDGLMadrigal Pharmaceuticals 2.90Moderate Buy$483.3811.84% UpsideCurrent Analyst Ratings BreakdownLatest LABU, MDGL, ARWR, and LABD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025MDGLMadrigal PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$428.00 ➝ $526.009/4/2025MDGLMadrigal PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$500.009/2/2025ARWRArrowhead PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.008/26/2025MDGLMadrigal PharmaceuticalsCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/26/2025MDGLMadrigal PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$390.00 ➝ $554.008/20/2025MDGLMadrigal PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$483.00 ➝ $485.008/12/2025MDGLMadrigal PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$458.00 ➝ $523.008/11/2025ARWRArrowhead PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/11/2025ARWRArrowhead PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.008/8/2025ARWRArrowhead PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$40.00 ➝ $38.008/6/2025MDGLMadrigal PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$420.00 ➝ $428.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARWRArrowhead Pharmaceuticals$3.55M1,157.49N/AN/A$1.54 per share19.30LABDDirexion Daily S&P Biotech Bear 3x SharesN/AN/AN/AN/AN/AN/ALABUDirexion Daily S&P Biotech Bull 3x SharesN/AN/AN/AN/AN/AN/AMDGLMadrigal Pharmaceuticals$180.13M53.27N/AN/A$34.59 per share12.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARWRArrowhead Pharmaceuticals-$599.49M-$1.28N/AN/AN/AN/A-40.91%-11.62%11/25/2025 (Estimated)LABDDirexion Daily S&P Biotech Bear 3x SharesN/AN/A0.00∞N/AN/AN/AN/AN/ALABUDirexion Daily S&P Biotech Bull 3x SharesN/AN/A0.00∞N/AN/AN/AN/AN/AMDGLMadrigal Pharmaceuticals-$465.89M-$12.85N/AN/AN/A-54.68%-38.38%-27.32%10/30/2025 (Estimated)Latest LABU, MDGL, ARWR, and LABD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q3 2025ARWRArrowhead Pharmaceuticals-$0.94-$1.26-$0.32-$1.26$29.01 million$27.77 million8/5/2025Q2 2025MDGLMadrigal Pharmaceuticals-$3.48-$1.90+$1.58-$1.90$158.94 million$212.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/ALABDDirexion Daily S&P Biotech Bear 3x Shares$0.275.45%N/AN/AN/ALABUDirexion Daily S&P Biotech Bull 3x Shares$0.320.41%N/AN/AN/AMDGLMadrigal PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARWRArrowhead Pharmaceuticals0.394.874.87LABDDirexion Daily S&P Biotech Bear 3x SharesN/AN/AN/ALABUDirexion Daily S&P Biotech Bull 3x SharesN/AN/AN/AMDGLMadrigal Pharmaceuticals0.175.114.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARWRArrowhead Pharmaceuticals62.61%LABDDirexion Daily S&P Biotech Bear 3x SharesN/ALABUDirexion Daily S&P Biotech Bull 3x SharesN/AMDGLMadrigal Pharmaceuticals98.50%Insider OwnershipCompanyInsider OwnershipARWRArrowhead Pharmaceuticals4.30%LABDDirexion Daily S&P Biotech Bear 3x SharesN/ALABUDirexion Daily S&P Biotech Bull 3x SharesN/AMDGLMadrigal Pharmaceuticals21.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARWRArrowhead Pharmaceuticals400138.26 million132.31 millionOptionableLABDDirexion Daily S&P Biotech Bear 3x SharesN/A16.02 millionN/ANot OptionableLABUDirexion Daily S&P Biotech Bull 3x SharesN/A10.37 millionN/ANot OptionableMDGLMadrigal Pharmaceuticals9022.20 million17.43 millionOptionableLABU, MDGL, ARWR, and LABD HeadlinesRecent News About These CompaniesMarketBeat Week in Review – 09/08 - 09/12 (MDGL)...1 hour ago | marketbeat.comEP Wealth Advisors LLC Takes Position in Madrigal Pharmaceuticals, Inc. $MDGL4 hours ago | marketbeat.comA Glimpse Into The Expert Outlook On Madrigal Pharmaceuticals Through 6 AnalystsSeptember 12 at 10:48 AM | benzinga.comWilliam John Sibold Sells 7,279 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) StockSeptember 11 at 11:47 PM | marketbeat.comWoodline Partners LP Buys 8,316 Shares of Madrigal Pharmaceuticals, Inc. $MDGLSeptember 11 at 6:49 AM | marketbeat.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Hits New 12-Month High - What's Next?September 10 at 4:38 PM | marketbeat.comCoreWeave and Madrigal's Insider Trades Flash Bullish Signals (MDGL)...September 10 at 7:31 AM | marketbeat.comMadrigal Pharmaceuticals (NASDAQ:MDGL) CEO William John Sibold Sells 7,279 SharesSeptember 10 at 5:38 AM | insidertrades.comA Fresh Look at Madrigal Pharmaceuticals (MDGL) Valuation Following Recent Share Price MomentumSeptember 9, 2025 | finance.yahoo.comWhat is HC Wainwright's Forecast for MDGL Q3 Earnings?September 9, 2025 | marketbeat.comMadrigal Pharmaceuticals, Inc. (MDGL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 8, 2025 | seekingalpha.comCinctive Capital Management LP Reduces Position in Madrigal Pharmaceuticals, Inc. $MDGLSeptember 8, 2025 | marketbeat.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Receives Buy Rating from HC WainwrightSeptember 6, 2025 | marketbeat.comCutter Capital Management LP Purchases New Shares in Madrigal Pharmaceuticals, Inc. $MDGLSeptember 6, 2025 | marketbeat.comAllostery Investments LP Buys Shares of 600 Madrigal Pharmaceuticals, Inc. $MDGLSeptember 5, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Has $63.47 Million Holdings in Madrigal Pharmaceuticals, Inc. $MDGLSeptember 5, 2025 | marketbeat.comMadrigal Pharmaceuticals assumed with a Buy at H.C. WainwrightSeptember 4, 2025 | msn.comTD Cowen Sees Greater Upside in Madrigal (MDGL) Following Recent Rezdiffra ApprovalSeptember 4, 2025 | msn.comMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)September 4, 2025 | globenewswire.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Sets New 52-Week High - What's Next?September 4, 2025 | marketbeat.comADAR1 Capital Management LLC Invests $494,000 in Madrigal Pharmaceuticals, Inc. $MDGLSeptember 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLABU, MDGL, ARWR, and LABD Company DescriptionsArrowhead Pharmaceuticals NASDAQ:ARWR$29.72 0.00 (0.00%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$29.80 +0.08 (+0.27%) As of 09/12/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Direxion Daily S&P Biotech Bear 3x Shares NYSEARCA:LABD$4.95 +0.23 (+4.87%) Closing price 09/12/2025 04:10 PM EasternExtended Trading$4.93 -0.02 (-0.40%) As of 09/12/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The Direxion Daily S&P Biotech Bear 3X Shares (LABD) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund provides daily 3 times inverse exposure to the S&P Biotechnology Select Industry Index. LABD was launched on May 28, 2015 and is managed by Direxion.Direxion Daily S&P Biotech Bull 3x Shares NYSEARCA:LABU$78.72 -4.02 (-4.86%) Closing price 09/12/2025 04:10 PM EasternExtended Trading$79.14 +0.42 (+0.54%) As of 09/12/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The Direxion Daily S&P Biotech Bull 3X Shares (LABU) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund provides daily 3 times exposure to the S&P Biotechnology Select Industry Index. LABU was launched on May 28, 2015 and is managed by Direxion.Madrigal Pharmaceuticals NASDAQ:MDGL$432.22 -7.23 (-1.65%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$432.16 -0.06 (-0.01%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
